Reduced inducibility of SOCS3 by interferon gamma associates with higher resistance of human breast cancer lines as compared to normal mammary epithelial cells.

The resistance to interferons (IFNs) limits their anticancer therapeutic efficacy. Here we studied the antiproliferative effect of interferon gamma in relation to SOCS3 expression in a panel of breast cancer cell lines and normal mammary epithelial cells. Compared to normal cells most breast cancer lines (7/8) were highly resistant to IFN-gamma. Using Northern blot and real time RT-PCR we investigated transcription of SOCS3 genes. All normal epithelial cells (4/4) showed SOCS3 induction (2-14 fold) while most breast cancer lines did not or weakly activated SOCS3 after the interferon gamma treatment. Among the cancer lines, the MDA-MB-468 cells showed increased sensitivity to IFN-gamma and relatively high level of SOCS3 induction (2-3 fold). Together, there was a good correlation

[1]  H. Kawachi,et al.  Decreased expression of SOCS-3 mRNA in breast cancer with lymph node metastasis. , 2008, Oncology reports.

[2]  J. Kovarik,et al.  Development of IFN-γ resistance is associated with attenuation of SOCS genes induction and constitutive expression of SOCS 3 in melanoma cells , 2007, British Journal of Cancer.

[3]  W. Gerald,et al.  Stat3 is tyrosine-phosphorylated through the interleukin-6/glycoprotein 130/Janus kinase pathway in breast cancer , 2007, Breast Cancer Research.

[4]  X. Liu,et al.  Expression of SOCS1 and SOCS3 genes is differentially regulated in breast cancer cells in response to proinflammatory cytokine and growth factor signals , 2007, Oncogene.

[5]  P. Heinrich,et al.  Constitutive Suppressor of Cytokine Signaling 3 Expression Confers a Growth Advantage to a Human Melanoma Cell Line , 2007, Molecular Cancer Research.

[6]  S. Eschrich,et al.  Persistent Activation of Stat3 Signaling Induces Survivin Gene Expression and Confers Resistance to Apoptosis in Human Breast Cancer Cells , 2006, Clinical Cancer Research.

[7]  J. Kovarik,et al.  Interferon-gamma, but not interferon-alpha, induces SOCS 3 expression in human melanoma cell lines. , 2005, Melanoma research.

[8]  Aseem Kumar,et al.  Stat1-independent induction of SOCS-3 by interferon-gamma is mediated by sustained activation of Stat3 in mouse embryonic fibroblasts. , 2005, Biochemical and biophysical research communications.

[9]  C. Geisler,et al.  Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNα , 2005, Leukemia.

[10]  Sergio Wittlin,et al.  Differential hypermethylation of SOCS genes in ovarian and breast carcinomas , 2004, Oncogene.

[11]  A. Yoshimura,et al.  Analysis of SOCS-3 Promoter Responses to Interferon γ* , 2004, Journal of Biological Chemistry.

[12]  A. Bosserhoff,et al.  Interferon-gamma-mediated growth regulation of melanoma cells: involvement of STAT1-dependent and STAT1-independent signals. , 2004, The Journal of investigative dermatology.

[13]  C. Watson.  Stat Transcription Factors in Mammary Gland Development and Tumorigenesis , 2004, Journal of Mammary Gland Biology and Neoplasia.

[14]  T. Naka,et al.  Regulation of cytokine signaling by SOCS family molecules. , 2003, Trends in immunology.

[15]  Biao He,et al.  SOCS-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Nicola Gebbia,et al.  STAT proteins: From normal control of cellular events to tumorigenesis , 2003, Journal of cellular physiology.

[17]  K. Shuai,et al.  Regulation of JAK–STAT signalling in the immune system , 2003, Nature Reviews Immunology.

[18]  J. Kovarik,et al.  Malignant melanoma associates with deficient IFN-induced STAT 1 phosphorylation. , 2003, International journal of molecular medicine.

[19]  M. Waters,et al.  Suppressor of cytokine signalling gene expression is elevated in breast carcinoma , 2003, British Journal of Cancer.

[20]  J. Kovarik,et al.  Interferon inducibility of STAT 1 activation and its prognostic significance in melanoma patients. , 2003, Folia biologica.

[21]  S. Fujita,et al.  Constitutive expression of SOCS3 confers resistance to IFN-alpha in chronic myelogenous leukemia cells. , 2002, Blood.

[22]  Giampiero Girolomoni,et al.  Impaired IFN-γ-Dependent Inflammatory Responses in Human Keratinocytes Overexpressing the Suppressor of Cytokine Signaling 11 , 2002, The Journal of Immunology.

[23]  C. Bucana,et al.  Stat1 negatively regulates angiogenesis, tumorigenicity and metastasis of tumor cells , 2002, Oncogene.

[24]  S. Bhattacharya,et al.  Signaling through the JAK/STAT pathway, recent advances and future challenges. , 2002, Gene.

[25]  J. Kovarik,et al.  JAK/STAT signaling pathways and cancer. Janus kinases/signal transducers and activators of transcription. , 2002, Neoplasma.

[26]  J. Ihle.  The Stat family in cytokine signaling. , 2001, Current opinion in cell biology.

[27]  Roy Garcia,et al.  STATs in oncogenesis , 2000, Oncogene.

[28]  J. Bromberg.  Signal transducers and activators of transcription as regulators of growth, apoptosis and breast development , 2000, Breast Cancer Research.

[29]  W. Alexander,et al.  Suppressors of cytokine signaling (SOCS): negative regulators of signal transduction , 1999, Journal of leukocyte biology.

[30]  D. Hilton,et al.  Negative regulators of cytokine signal transduction , 1999, Cellular and Molecular Life Sciences CMLS.

[31]  U. Klingmüller,et al.  Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells is STAT-dependent and involves upregulation of the cyclin-dependent kinase inhibitor p27/Kip1 , 1999, Oncogene.

[32]  R. Jove,et al.  Constitutive activation of Stat3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[33]  H. Sakamoto,et al.  Cloning and characterization of novel CIS family genes. , 1997, Biochemical and biophysical research communications.

[34]  J. Darnell.  STATs and gene regulation. , 1997, Science.

[35]  R. Pettengell,et al.  INTERFERONS IN ONCOLOGY , 1997, The British journal of clinical practice.

[36]  H. Strander,et al.  Interferon treatment of human malignancies - a short review , 1993, Medical oncology and tumor pharmacotherapy.